智通财经APP讯,复星医药(600196.SH)公告,公司控股子公司重庆凯林制药有限公司就硫代硫酸钠注射液的药品注册申请获国家药品监督管理局批准。本次获批适应症为用于氰化物中毒,也可用于砷、汞、铅、铋、碘等中毒。
更多港股重磅资讯,下载智通财经app
更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)
智通财经APP讯,复星医药(600196.SH)公告,公司控股子公司重庆凯林制药有限公司就硫代硫酸钠注射液的药品注册申请获国家药品监督管理局批准。本次获批适应症为用于氰化物中毒,也可用于砷、汞、铅、铋、碘等中毒。
更多港股重磅资讯,下载智通财经app
更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.